Amicus Therapeutics Inc. (FOLD: Quote) and GlaxoSmithKline (GSK: Quote) announced the 6-month primary treatment period results from the first Phase 3 study of oral migalastat HCl monotherapy in males and females with Fabry disease. The study did not achieve statistical significance according to the pre-specified primary endpoint analysis.
Amicus Therapeutics traded in a narrow range throughout Wednesday's session and finished up by 0.11 at $5.77. The stock is now down 2.80 on 637K shares after the bell.
Click here to receive FREE breaking news email alerts for AMICUS THERAPEUTICS INC and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com